The role of vitamin D in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure

Giuseppe Vezzoli, Teresa Arcidiacono, Mario Cozzolino

Research output: Contribution to journalArticle

Abstract

Chronic renal failure (CRF) causes alterations in calcium-phosphate metabolism promoting the development of secondary hyperparathyroidism (HPT) and renal osteodystrophy. Recent data suggest that these alterations may play a crucial role in determining cardiovascular calcifications and, thus, cardiovascular mortality among CRF patients. An impaired 1α-hydroxylation of 25-hydroxycholecalciferol (25(OH)D) to 1,25-dihydroxycholecalciferol (1,25(OH)2D) with decreased circulating 1,25(OH)2D levels is commonly observed in patients with creatinine clearance below 70 ml/min. The reduction in 1,25(OH)2D production triggers the upregulation of PTH synthesis, through a decreased suppression on PTH gene transcription and a decreased intestinal calcium absorption. Low vitamin D stores often contribute to the decrease in production and tissue resistance to vitamin D worsens 1,25(OH)2D deficiency. A reduced expression of vitamin D receptor (VDR) and a less efficient binding of the complex 1,25(OH)2D-VDR to specific DNA segments account for the resistance to 1,25(OH)2D in target cells. Thus, absolute and relative 1,25(OH)2D deficiency is one of the causes of secondary HPT in patients with CRF, together with phosphate retention and skeletal resistance to PTH. Consistently with these pathophysiological mechanisms, the therapeutic use of 1,25(OH)2D still represents a milestone for the treatment of uremic secondary HPT and renal osteodystrophy, even though hypercalcemia and hyperphosphatemia are common adverse events and may increase the risk of cardiovascular calcifications. Furthermore, adynamic bone disease may develop after vitamin D therapy. Low levels of serum 25(OH)D are associated with more severe osteodystrophy and HPT, even among dialysis patients. To separate these adverse effects from anti-PTH activity, 1,25(OH)2D analogues with lower hypercalcemic effect have been synthesized and are now available for clinical use.

Original languageEnglish
Pages (from-to)60-70
Number of pages11
JournalClinical Cases in Mineral and Bone Metabolism
Volume3
Issue number1
Publication statusPublished - Jan 2006

Fingerprint

Calcifediol
Secondary Hyperparathyroidism
Vitamin D
Chronic Kidney Failure
Chronic Kidney Disease-Mineral and Bone Disorder
Calcitriol Receptors
Hyperphosphatemia
Hyperparathyroidism
Calcitriol
Bone Diseases
Intestinal Absorption
Hypercalcemia
Therapeutic Uses
Hydroxylation
Dialysis
Creatinine
Up-Regulation
Phosphates

Keywords

  • Calcium
  • Chronic renal failure
  • Parathyroid hormone
  • Phosphate
  • Vitamin D

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

The role of vitamin D in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure. / Vezzoli, Giuseppe; Arcidiacono, Teresa; Cozzolino, Mario.

In: Clinical Cases in Mineral and Bone Metabolism, Vol. 3, No. 1, 01.2006, p. 60-70.

Research output: Contribution to journalArticle

@article{8f97d068e0f1416488f3492d39b397c9,
title = "The role of vitamin D in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure",
abstract = "Chronic renal failure (CRF) causes alterations in calcium-phosphate metabolism promoting the development of secondary hyperparathyroidism (HPT) and renal osteodystrophy. Recent data suggest that these alterations may play a crucial role in determining cardiovascular calcifications and, thus, cardiovascular mortality among CRF patients. An impaired 1α-hydroxylation of 25-hydroxycholecalciferol (25(OH)D) to 1,25-dihydroxycholecalciferol (1,25(OH)2D) with decreased circulating 1,25(OH)2D levels is commonly observed in patients with creatinine clearance below 70 ml/min. The reduction in 1,25(OH)2D production triggers the upregulation of PTH synthesis, through a decreased suppression on PTH gene transcription and a decreased intestinal calcium absorption. Low vitamin D stores often contribute to the decrease in production and tissue resistance to vitamin D worsens 1,25(OH)2D deficiency. A reduced expression of vitamin D receptor (VDR) and a less efficient binding of the complex 1,25(OH)2D-VDR to specific DNA segments account for the resistance to 1,25(OH)2D in target cells. Thus, absolute and relative 1,25(OH)2D deficiency is one of the causes of secondary HPT in patients with CRF, together with phosphate retention and skeletal resistance to PTH. Consistently with these pathophysiological mechanisms, the therapeutic use of 1,25(OH)2D still represents a milestone for the treatment of uremic secondary HPT and renal osteodystrophy, even though hypercalcemia and hyperphosphatemia are common adverse events and may increase the risk of cardiovascular calcifications. Furthermore, adynamic bone disease may develop after vitamin D therapy. Low levels of serum 25(OH)D are associated with more severe osteodystrophy and HPT, even among dialysis patients. To separate these adverse effects from anti-PTH activity, 1,25(OH)2D analogues with lower hypercalcemic effect have been synthesized and are now available for clinical use.",
keywords = "Calcium, Chronic renal failure, Parathyroid hormone, Phosphate, Vitamin D",
author = "Giuseppe Vezzoli and Teresa Arcidiacono and Mario Cozzolino",
year = "2006",
month = "1",
language = "English",
volume = "3",
pages = "60--70",
journal = "Clinical Cases in Mineral and Bone Metabolism",
issn = "1724-8914",
publisher = "CIC Edizioni Internazionali s.r.l.",
number = "1",

}

TY - JOUR

T1 - The role of vitamin D in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure

AU - Vezzoli, Giuseppe

AU - Arcidiacono, Teresa

AU - Cozzolino, Mario

PY - 2006/1

Y1 - 2006/1

N2 - Chronic renal failure (CRF) causes alterations in calcium-phosphate metabolism promoting the development of secondary hyperparathyroidism (HPT) and renal osteodystrophy. Recent data suggest that these alterations may play a crucial role in determining cardiovascular calcifications and, thus, cardiovascular mortality among CRF patients. An impaired 1α-hydroxylation of 25-hydroxycholecalciferol (25(OH)D) to 1,25-dihydroxycholecalciferol (1,25(OH)2D) with decreased circulating 1,25(OH)2D levels is commonly observed in patients with creatinine clearance below 70 ml/min. The reduction in 1,25(OH)2D production triggers the upregulation of PTH synthesis, through a decreased suppression on PTH gene transcription and a decreased intestinal calcium absorption. Low vitamin D stores often contribute to the decrease in production and tissue resistance to vitamin D worsens 1,25(OH)2D deficiency. A reduced expression of vitamin D receptor (VDR) and a less efficient binding of the complex 1,25(OH)2D-VDR to specific DNA segments account for the resistance to 1,25(OH)2D in target cells. Thus, absolute and relative 1,25(OH)2D deficiency is one of the causes of secondary HPT in patients with CRF, together with phosphate retention and skeletal resistance to PTH. Consistently with these pathophysiological mechanisms, the therapeutic use of 1,25(OH)2D still represents a milestone for the treatment of uremic secondary HPT and renal osteodystrophy, even though hypercalcemia and hyperphosphatemia are common adverse events and may increase the risk of cardiovascular calcifications. Furthermore, adynamic bone disease may develop after vitamin D therapy. Low levels of serum 25(OH)D are associated with more severe osteodystrophy and HPT, even among dialysis patients. To separate these adverse effects from anti-PTH activity, 1,25(OH)2D analogues with lower hypercalcemic effect have been synthesized and are now available for clinical use.

AB - Chronic renal failure (CRF) causes alterations in calcium-phosphate metabolism promoting the development of secondary hyperparathyroidism (HPT) and renal osteodystrophy. Recent data suggest that these alterations may play a crucial role in determining cardiovascular calcifications and, thus, cardiovascular mortality among CRF patients. An impaired 1α-hydroxylation of 25-hydroxycholecalciferol (25(OH)D) to 1,25-dihydroxycholecalciferol (1,25(OH)2D) with decreased circulating 1,25(OH)2D levels is commonly observed in patients with creatinine clearance below 70 ml/min. The reduction in 1,25(OH)2D production triggers the upregulation of PTH synthesis, through a decreased suppression on PTH gene transcription and a decreased intestinal calcium absorption. Low vitamin D stores often contribute to the decrease in production and tissue resistance to vitamin D worsens 1,25(OH)2D deficiency. A reduced expression of vitamin D receptor (VDR) and a less efficient binding of the complex 1,25(OH)2D-VDR to specific DNA segments account for the resistance to 1,25(OH)2D in target cells. Thus, absolute and relative 1,25(OH)2D deficiency is one of the causes of secondary HPT in patients with CRF, together with phosphate retention and skeletal resistance to PTH. Consistently with these pathophysiological mechanisms, the therapeutic use of 1,25(OH)2D still represents a milestone for the treatment of uremic secondary HPT and renal osteodystrophy, even though hypercalcemia and hyperphosphatemia are common adverse events and may increase the risk of cardiovascular calcifications. Furthermore, adynamic bone disease may develop after vitamin D therapy. Low levels of serum 25(OH)D are associated with more severe osteodystrophy and HPT, even among dialysis patients. To separate these adverse effects from anti-PTH activity, 1,25(OH)2D analogues with lower hypercalcemic effect have been synthesized and are now available for clinical use.

KW - Calcium

KW - Chronic renal failure

KW - Parathyroid hormone

KW - Phosphate

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=33750902180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750902180&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33750902180

VL - 3

SP - 60

EP - 70

JO - Clinical Cases in Mineral and Bone Metabolism

JF - Clinical Cases in Mineral and Bone Metabolism

SN - 1724-8914

IS - 1

ER -